Thinly traded nano cap EyeGate Pharmaceuticals (NASDAQ:EYEG) jumps 67% premarket on light volume in reaction to its announcement that the FDA has clarified a development path for MoxiGel, a combination of its Ocular Bandage Gel and an antibiotic, for the potential treatment of bacterial conjunctivitis.
An IND is on tap for H1 2021.
Ocular Bandage Gel, based on a modified form of the natural polymer hyaluronic acid, is designed to stay on the corneal surface longer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.